Singapore markets open in 3 hours 59 minutes
  • Straits Times Index

    3,201.86
    -3.28 (-0.10%)
     
  • S&P 500

    4,566.48
    +21.58 (+0.47%)
     
  • Dow

    35,741.15
    +64.13 (+0.18%)
     
  • Nasdaq

    15,226.71
    +136.51 (+0.90%)
     
  • BTC-USD

    62,588.63
    +1,380.02 (+2.25%)
     
  • CMC Crypto 200

    1,502.82
    +1,260.14 (+519.26%)
     
  • FTSE 100

    7,222.82
    +18.27 (+0.25%)
     
  • Gold

    1,808.50
    +12.20 (+0.68%)
     
  • Crude Oil

    83.64
    -0.12 (-0.14%)
     
  • 10-Yr Bond

    1.6350
    -0.0200 (-1.21%)
     
  • Nikkei

    28,600.41
    -204.44 (-0.71%)
     
  • Hang Seng

    26,132.03
    +5.10 (+0.02%)
     
  • FTSE Bursa Malaysia

    1,587.94
    -0.14 (-0.01%)
     
  • Jakarta Composite Index

    6,625.70
    -18.04 (-0.27%)
     
  • PSE Index

    7,211.54
    -78.07 (-1.07%)
     

Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Agios Pharmaceuticals, Inc. AGIO announced that the FDA has accepted the new drug application for its lead pipeline candidate, mitapivat, for priority review. The NDA is seeking the approval of the candidate as a potential treatment of adult patients with pyruvate kinase (“PK”) deficiency, a rare, inherited disease. Currently, there is no treatment approved for the given indication.

The priority review has reduced the anticipated timeline for review of mitapivat NDA from 10 months to six months. The FDA will announce its decision onthepotential approval for mitapivat by Feb 17, 2022.

Shares of Agios were up nearly 3% during after-hours trading on Aug 17 with the FDA granting priority review tag to the NDA. The company’s shares have gained 3.1% so far this year compared with the industry’s increase of 3.6%.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

The NDA was based on data from two pivotal phase III studies – ACTIVATE and ACTIVATE-T – which evaluated mitapivat for treating PK deficiency in adults who are not regularly transfused and those who are regularly transfused, respectively.

A marketing authorization application, seeking approval of mitapivat for treating adults with PK deficiency in Europe,is also under review.

Upon potential approval and launch, mitapivat can provide a first potentially disease-modifying therapy for people with PK deficiency, thereby serving an area of high unmet medical need. However, the company’s operating expenses will likely go higher in the upcoming quarters to support pre-commercialization and commercialization activities for mitapivat. Moreover, the company is also conducting several clinical studies to support the approval of mitapivat in other hemolytic anemias indications.

A phase II/III study on mitapivat for sickle cell disease is expected to begin by year-end. The company also plans to initiate two phase III studies on mitapivat in thalassemia (regularly transfused as well as not regularly transfused) this year.

We remind investors that Agios completed the sale of its oncology portfolio to France-based pharmaceutical company, Servier, in March 2021. Following this sale, the company’s sole focus now remains on expanding its genetically defined disease portfolio, including the clinical development of mitapivat.

This apart, Agios is also evaluating AG-946, its next-generation pyruvate kinase-R activator, in a phase I study for the treatment of hemolytic anemia.

Agios Pharmaceuticals, Inc. Price

Agios Pharmaceuticals, Inc. Price
Agios Pharmaceuticals, Inc. Price

Agios Pharmaceuticals, Inc. price | Agios Pharmaceuticals, Inc. Quote

Zacks Rank & Stocks to Consider

Currently, Agios has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the biotech/drug sector include Horizon Therapeutics HZNP, Repligen Corporation RGEN and Aptose Biosciences APTO. While Horizon sports a Zacks Rank #1 (Strong Buy), Repligen and Aptose currently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Horizon’s earnings per share estimates for 2021 have increased from $3.62 to $4.46 in the past 30 days while that for 2022 have increased from $5.18 to $5.84 over the same period. The stock has risen 44.2% in the year so far.

Repligen’s earnings per share estimates for 2021 have increased from $2.26 to $2.76 in the past 30 days while that for 2022 have increased from $2.56 to $3.02 over the same period. The stock has risen 34.1% in the year so far.

Aptose’s loss per share estimates for 2021 have narrowed from 76 cents to 68 cents in the past 30 days while that for 2022 have narrowed from 96 cents to 92 cents over the same period.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Horizon Therapeutics Public Limited Company (HZNP) : Free Stock Analysis Report

Repligen Corporation (RGEN) : Free Stock Analysis Report

Agios Pharmaceuticals, Inc. (AGIO) : Free Stock Analysis Report

Aptose Biosciences, Inc. (APTO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting